VX-11e
Based on 10 publication(s) in Google Scholar
VX-11e is a potent, selective, and orally bioavailable inhibitor of ERK with Ki < 2 nM.
For research use only. We do not sell to patients.
- Purity : 98.94%
- CAS No.: 896720-20-0
- Formula: C24H20Cl2FN5O2
- Molecular Weight:500.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-15816
UlixertinibERK1/2 Inhibitor -
HY-50846
SCH772984ERK1/2 Inhibitor -
HY-15947
RavoxertinibERK1/2 Inhibitor -
HY-101494
TemuterkibERK1/ERK2 Inhibitor -
HY-18932
DEL-22379ERK Dimerization Inhibitor -
HY-111483
Tizaterkib -
HY-108330
AG126Tyrosine Kinase Inhibitor -
HY-112181
KO-947ERK1/2 Inhibitor -
HY-15665
XMD17-109ERK-5 Inhibitor -
HY-15816R
Ulixertinib (Standard)ERK1/2 Inhibitor -
HY-12275
FR 180204ERK Inhibitor -
HY-50767
PalbociclibCDK4/6 Inhibitor
Publications Citing Use of MedChemExpress (MCE) VX-11e
More- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. [Abstract]
- Cell Rep Med. 2025 Feb 18;6(2):101970. [Abstract]
- Cell Death Dis. 2022 May 12;13(5):451. [Abstract]
- J Invest Dermatol. 2021 Apr;141(4):852-862.e6. [Abstract]
- Sci Rep. 2025 Jan 6;15(1):954. [Abstract]
- BMC Cancer. 2026 May 4;26(1):768. [Abstract]
- Stem Cells Dev. 2020 Jul 1;29(13):863-875. [Abstract]
- ACS Comb Sci. 2019 Dec 9;21(12):805-816. [Abstract]
- Oncotarget. 2016 Apr 26;7(17):23300-11. [Abstract]
- J Prac Med. 2016, 32 (11): 1734-1737.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
Biological Activity
Description
IC50 & Target
[1]|
ERK2 2 nM (Ki) |
GSK3 395 (Ki) |
AURA 540 (Ki) |
CDK2 852 (Ki) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | IC50 |
48 nM
Compound: 11e
|
Antiproliferative activity against human HT-29 cells
Antiproliferative activity against human HT-29 cells
|
[PMID: 19827834] |
In Vitro
VX-11e is active in the HT29 cell proliferation assay (IC50=48 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 896720-20-0
-
Appearance Solid
-
Molecular Weight 500.35
-
Formula C24H20Cl2FN5O2
-
Color White to off-white
-
SMILES
FC1=CC(Cl)=C(NC2=NC(C3=CNC(C(N[C@H](CO)C4=CC=CC(Cl)=C4)=O)=C3)=C(C)C=N2)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Sci Transl Med
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]2018 Jul 18;10(450):eaaq1093. PMID: 30021885 -
Cell Rep Med
2025 Feb 18;6(2):101970. PMID: 39938523 -
Cell Death Dis
2022 May 12;13(5):451. PMID: 35551175 -
J Invest Dermatol
Inhibition of the Extracellular Signal-Regulated Kinase/Ribosomal S6 Kinase Cascade Limits Chlamydia trachomatis Infection. [Abstract]2021 Apr;141(4):852-862.e6. PMID: 32918951 -
Sci Rep
Super-enhancer-driven SLCO4A1-AS1 is a new biomarker and a promising therapeutic target in glioblastoma. [Abstract]2025 Jan 6;15(1):954. PMID: 39762261 -
BMC Cancer
PPP4C: a potential molecular marker and therapeutic target in thyroid cancer and triple-negative breast cancer. [Abstract]2026 May 4;26(1):768. PMID: 42082953 -
Stem Cells Dev
Zinc Promotes Patient-Derived Induced Pluripotent Stem Cell Neural Differentiation via ERK-STAT Signaling. [Abstract]2020 Jul 1;29(13):863-875. PMID: 32323639 -
ACS Comb Sci
Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]2019 Dec 9;21(12):805-816. PMID: 31689077 -
Oncotarget
MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. [Abstract]2016 Apr 26;7(17):23300-11. PMID: 27004400
VX-11e purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Apr 26;7(17):23300-11. [Abstract]
A. HNSCC cells are treated with DMSO vehicle or VX-11e (0.5 μM) for 24 h and cell protein extracts analyzed. VX-11e inhibits phosphorylation of RSK1 in Cal33 and HSC-6. B. VX-11e inhibits phosphorylation of RSK1 in FaDu engineered cells.
-
VX-11e purchased from MedChemExpress. Usage Cited in: J Prac Med. 2016, 32 (11): 1734-1737.
Signaling pathways analysis of effects of BSP on RAW264.7 cells proliferation.
Solvent & Solubility
In Vitro:
DMSO : ≥ 100 mg/mL (199.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3.25 mg/mL (6.50 mM); Clear solution
This protocol yields a clear solution of ≥ 3.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (32.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9986 mL | 9.9930 mL | 19.9860 mL | 49.9650 mL |
| 5 mM | 0.3997 mL | 1.9986 mL | 3.9972 mL | 9.9930 mL | |
| 10 mM | 0.1999 mL | 0.9993 mL | 1.9986 mL | 4.9965 mL | |
| 15 mM | 0.1332 mL | 0.6662 mL | 1.3324 mL | 3.3310 mL | |
| 20 mM | 0.0999 mL | 0.4997 mL | 0.9993 mL | 2.4983 mL | |
| 25 mM | 0.0799 mL | 0.3997 mL | 0.7994 mL | 1.9986 mL | |
| 30 mM | 0.0666 mL | 0.3331 mL | 0.6662 mL | 1.6655 mL | |
| 40 mM | 0.0500 mL | 0.2498 mL | 0.4997 mL | 1.2491 mL | |
| 50 mM | 0.0400 mL | 0.1999 mL | 0.3997 mL | 0.9993 mL | |
| 60 mM | 0.0333 mL | 0.1666 mL | 0.3331 mL | 0.8328 mL | |
| 80 mM | 0.0250 mL | 0.1249 mL | 0.2498 mL | 0.6246 mL | |
| 100 mM | 0.0200 mL | 0.0999 mL | 0.1999 mL | 0.4997 mL |
VX-11e Related Classifications
HY-14178 Related Classifications
Powered by Bioz